Abstract: Bridges 30, 40 are interposed between a server 10 or a client 20 having two channels 2ch, one of the two channels making a LAN connection to either the server or the client and the other channel making the LAN connection to the internet. Each of bridges 30, 40 performs a LAN packet scramble, a scramble purpose encryption key management, a scramble purpose encryption key management, and a bridging system authentication. Furthermore, each of bridges 30, 40 performs a LAN packet scramble, a scramble purpose encryption key management, and a bridging system authentication for a packet derived from the server or the client. Furthermore, a composite authentication having a plurality of authentication purpose interfaces is carried out in each of the bridges. Furthermore, a composite authentication having a plurality of authentication purpose interfaces is carried out in each of the bridges. The bridge has a plurality of authentication purpose interfaces to perform a composite authentication.

Abstract: Bridges 30, 40 are interposed between a server 10 or a client 20 having two channels 2ch, one of the two channels making a LAN connection to either the server or the client and the other channel making the LAN connection to the internet. Each of bridges 30, 40 performs a LAN packet scramble, a scramble purpose encryption key management, a scramble purpose encryption key management, and a bridging system authentication. Furthermore, each of bridges 30, 40 performs a LAN packet scramble, a scramble purpose encryption key management, and a bridging system authentication for a packet derived from the server or the client. Furthermore, a composite authentication having a plurality of authentication purpose interfaces is carried out in each of the bridges. Furthermore, a composite authentication having a plurality of authentication purpose interfaces is carried out in each of the bridges. The bridge has a plurality of authentication purpose interfaces to perform a composite authentication.

Abstract: The compounds represented by the formula (I), and pharmacologically acceptable salts and solvates thereof are disclosed. The compound is hydrolyzed in organisms into a compound represented by the formula in which W represents a hydrogen atom, and D represents the group —V—(CH2)p—COOR, wherein R represents a hydrogen atom. The compound inhibits the aggregation of platelets via the inhibition of the linkage of the platelet membrane protein GPIIb/IIIa to fibrinogen. wherein A represents CH2 or CO, B represents the group —(CH2)k— or —(CH2)m—CO—, X and Y are different from each other and represent N or CH, W represents an ester moiety which can be removed under the physiological condition, and Z represents the groups (II) or (III): wherein D represents the group —V—(CH2)p—COOR.